283 related articles for article (PubMed ID: 20226822)
21. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
Désormeaux A; Bergeron MG
Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
[TBL] [Abstract][Full Text] [Related]
22. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
23. Targeted lipoplexes for siRNA delivery.
Cardoso A; Trabulo S; Moreira JN; Düzgüneş N; de Lima MC
Methods Enzymol; 2009; 465():267-87. PubMed ID: 19913172
[TBL] [Abstract][Full Text] [Related]
24. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
25. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes.
Woo J; Chiu GN; Karlsson G; Wasan E; Ickenstein L; Edwards K; Bally MB
Int J Pharm; 2008 Feb; 349(1-2):38-46. PubMed ID: 17728083
[TBL] [Abstract][Full Text] [Related]
26. [Cationic liposomes loaded with doxorubicin targeting to the tumor neovasculature in vitro].
Zhao W; Ma HL; Qi XR
Yao Xue Xue Bao; 2007 Sep; 42(9):982-8. PubMed ID: 18050743
[TBL] [Abstract][Full Text] [Related]
27. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
28. Development of a liposomal formulation of the natural flavonoid fisetin.
Mignet N; Seguin J; Ramos Romano M; Brullé L; Touil YS; Scherman D; Bessodes M; Chabot GG
Int J Pharm; 2012 Feb; 423(1):69-76. PubMed ID: 21571054
[TBL] [Abstract][Full Text] [Related]
29. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells.
Mai J; Song S; Rui M; Liu D; Ding Q; Peng J; Xu Y
J Control Release; 2009 Nov; 139(3):174-81. PubMed ID: 19576253
[TBL] [Abstract][Full Text] [Related]
30. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
[TBL] [Abstract][Full Text] [Related]
31. Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery.
Tagalakis AD; He L; Saraiva L; Gustafsson KT; Hart SL
Biomaterials; 2011 Sep; 32(26):6302-15. PubMed ID: 21624650
[TBL] [Abstract][Full Text] [Related]
32. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment.
Mendonça LS; Firmino F; Moreira JN; Pedroso de Lima MC; Simões S
Bioconjug Chem; 2010 Jan; 21(1):157-68. PubMed ID: 20000596
[TBL] [Abstract][Full Text] [Related]
33. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
34. E-selectin binding peptide-polymer-drug conjugates and their selective cytotoxicity against vascular endothelial cells.
Shamay Y; Paulin D; Ashkenasy G; David A
Biomaterials; 2009 Nov; 30(32):6460-8. PubMed ID: 19716600
[TBL] [Abstract][Full Text] [Related]
35. Surface-modified LPD nanoparticles for tumor targeting.
Li SD; Huang L
Ann N Y Acad Sci; 2006 Oct; 1082():1-8. PubMed ID: 17145918
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo gene-transferring characteristics of novel cationic lipids, DMKD (O,O'-dimyristyl-N-lysyl aspartate) and DMKE (O,O'-dimyristyl-N-lysyl glutamate).
Kim HS; Song IH; Kim JC; Kim EJ; Jang DO; Park YS
J Control Release; 2006 Oct; 115(2):234-41. PubMed ID: 16989919
[TBL] [Abstract][Full Text] [Related]
37. Pore forming polyalkylpyridinium salts from marine sponges versus synthetic lipofection systems: distinct tools for intracellular delivery of cDNA and siRNA.
McLaggan D; Adjimatera N; Sepcić K; Jaspars M; MacEwan DJ; Blagbrough IS; Scott RH
BMC Biotechnol; 2006 Jan; 6():6. PubMed ID: 16412248
[TBL] [Abstract][Full Text] [Related]
38. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect.
Wiradharma N; Tong YW; Yang YY
Biomaterials; 2009 Jun; 30(17):3100-9. PubMed ID: 19342093
[TBL] [Abstract][Full Text] [Related]
39. An immobilized nanoparticle-based platform for efficient gene knockdown of targeted cells in the circulation.
Huang Z; King MR
Gene Ther; 2009 Oct; 16(10):1271-82. PubMed ID: 19554031
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo.
Obata Y; Tajima S; Takeoka S
J Control Release; 2010 Mar; 142(2):267-76. PubMed ID: 19861141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
